Viral Hepatitis Market

Purchase Option

$ 4400
$ 6600
$ 8900

Viral Hepatitis Market Segmentation

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1. Executive Summary
2. Global Viral Hepatitis Introduction
2.1. Global Viral Hepatitis - Taxonomy
2.2. Global Viral Hepatitis - Definitions
2.2.1. By Type
2.2.2. By Treatment Type
2.2.3. By Region
3. Global Viral Hepatitis Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Key Developments
4. Global Viral Hepatitis By Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
4.1. Hepatitis A
4.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.3. Market Opportunity Analysis
4.2. Hepatitis B
4.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.3. Market Opportunity Analysis
4.3. Hepatitis C
4.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.3.3. Market Opportunity Analysis
4.4. Others
4.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.4.3. Market Opportunity Analysis
5. Global Viral Hepatitis By Treatment Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Antiviral Drugs
5.1.1. Telbivudine
5.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Entecavir
5.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Tenofovir disoproxil
5.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Lamivudine
5.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.1.5. Others
5.1.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.5.3. Market Opportunity Analysis
5.2. Vaccine
5.2.1. Immune Modulator Drugs
5.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Pegylated Interferon
5.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Interferon Alpha
5.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
5.3. Surgery
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Viral Hepatitis By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. North America
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Europe
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Asia Pacific
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Latin America
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. MEA
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Global Viral Hepatitis - Opportunity Analysis Index, By Treatment Type, Type, , , , , , and Region, 2023-2029
7. North America Viral Hepatitis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
7.1.1. Hepatitis A
7.1.2. Hepatitis B
7.1.3. Hepatitis C
7.1.4. Others
7.2. Treatment Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
7.2.1. Antiviral Drugs
7.2.1.1. Telbivudine
7.2.1.2. Entecavir
7.2.1.3. Tenofovir disoproxil
7.2.1.4. Lamivudine
7.2.1.5. Others
7.2.2. Vaccine
7.2.2.1. Immune Modulator Drugs
7.2.2.2. Pegylated Interferon
7.2.2.3. Interferon Alpha
7.2.3. Surgery
7.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
7.3.1. USA
7.3.2. Canada
8. Europe Viral Hepatitis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.1.1. Hepatitis A
8.1.2. Hepatitis B
8.1.3. Hepatitis C
8.1.4. Others
8.2. Treatment Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.2.1. Antiviral Drugs
8.2.1.1. Telbivudine
8.2.1.2. Entecavir
8.2.1.3. Tenofovir disoproxil
8.2.1.4. Lamivudine
8.2.1.5. Others
8.2.2. Vaccine
8.2.2.1. Immune Modulator Drugs
8.2.2.2. Pegylated Interferon
8.2.2.3. Interferon Alpha
8.2.3. Surgery
8.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.3.1. Germany
8.3.2. France
8.3.3. Italy
8.3.4. Spain
8.3.5. UK
8.3.6. Rest of Europe
9. Asia Pacific Viral Hepatitis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1. Hepatitis A
9.1.2. Hepatitis B
9.1.3. Hepatitis C
9.1.4. Others
9.2. Treatment Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1. Antiviral Drugs
9.2.1.1. Telbivudine
9.2.1.2. Entecavir
9.2.1.3. Tenofovir disoproxil
9.2.1.4. Lamivudine
9.2.1.5. Others
9.2.2. Vaccine
9.2.2.1. Immune Modulator Drugs
9.2.2.2. Pegylated Interferon
9.2.2.3. Interferon Alpha
9.2.3. Surgery
9.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1. China
9.3.2. Japan
9.3.3. South Korea
9.3.4. India
9.3.5. Rest of APAC
10. Latin America Viral Hepatitis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1. Hepatitis A
10.1.2. Hepatitis B
10.1.3. Hepatitis C
10.1.4. Others
10.2. Treatment Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1. Antiviral Drugs
10.2.1.1. Telbivudine
10.2.1.2. Entecavir
10.2.1.3. Tenofovir disoproxil
10.2.1.4. Lamivudine
10.2.1.5. Others
10.2.2. Vaccine
10.2.2.1. Immune Modulator Drugs
10.2.2.2. Pegylated Interferon
10.2.2.3. Interferon Alpha
10.2.3. Surgery
10.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Argentina
10.3.4. Rest of Latin America
11. MEA Viral Hepatitis, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1. Hepatitis A
11.1.2. Hepatitis B
11.1.3. Hepatitis C
11.1.4. Others
11.2. Treatment Type Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1. Antiviral Drugs
11.2.1.1. Telbivudine
11.2.1.2. Entecavir
11.2.1.3. Tenofovir disoproxil
11.2.1.4. Lamivudine
11.2.1.5. Others
11.2.2. Vaccine
11.2.2.1. Immune Modulator Drugs
11.2.2.2. Pegylated Interferon
11.2.2.3. Interferon Alpha
11.2.3. Surgery
11.3. Country Analysis, 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1. GCC Countries
11.3.2. South Africa
11.3.3. Rest of MEA
12. Competition Landscape
12.1. Strategic Dashboard of Top Market Players
12.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis)
12.2.1. Merck KGaA
12.2.2. Gilead Sciences Inc.
12.2.3. AbbVie Inc.
12.2.4. Bristol Myers Squibb Company
12.2.5. F Hoffmann-La Roche, Ltd
12.2.6. LAURUS Labs
12.2.7. Zydus Cadila
12.2.8. Hetero Healthcare Limited
12.2.9. NATCO Pharma Limited
12.2.10. Cipla Inc.
12.2.11. Johnson & Johnson
12.2.12. Biocon
13. Research Methodology
14. Key Assumptions and Acronyms
• Merck KGaA
• Gilead Sciences Inc.
• AbbVie Inc.
• Bristol Myers Squibb Company
• F Hoffmann-La Roche, Ltd
• LAURUS Labs
• Zydus Cadila
• Hetero Healthcare Limited
• NATCO Pharma Limited
• Cipla Inc.
• Johnson & Johnson
• Biocon

Adjacent Markets